Integra (IART) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Core Insights - Integra LifeSciences reported revenue of $402.06 million for Q3 2025, a year-over-year increase of 5.6% and an EPS of $0.54 compared to $0.41 a year ago, indicating positive growth in earnings [1] - The reported revenue fell short of the Zacks Consensus Estimate of $414.8 million, resulting in a surprise of -3.07%, while the EPS exceeded expectations by +25.58% [1] Revenue Breakdown - Organic revenue growth was reported at 5%, below the four-analyst average estimate of 8.5% [4] - Codman Specialty Surgical revenue totaled $292.58 million, compared to the estimated $300.46 million, reflecting an 8.1% year-over-year increase [4] - Tissue Technologies revenue was $109.48 million, below the estimated $114.4 million, showing a slight decline of -0.5% year-over-year [4] - Within Tissue Technologies, Wound Reconstruction and Care generated $83.99 million, slightly below the $84.83 million estimate, marking a +4.4% year-over-year change [4] - Private Label revenue was reported at $25.49 million, significantly lower than the $29.58 million estimate, representing a -13.9% year-over-year decline [4] Stock Performance - Shares of Integra have returned +4.8% over the past month, outperforming the Zacks S&P 500 composite's +3.6% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]